- Home
- EVAX vs ATHA Comparison
EVAX vs ATHA Comparison
Compare EVAX & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- ATHA
- Stock Information
- Founded
- EVAX 2008
- ATHA 2011
- Country
- EVAX Denmark
- ATHA United States
- Employees
- EVAX N/A
- ATHA N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- EVAX Health Care
- ATHA Health Care
- Exchange
- EVAX Nasdaq
- ATHA Nasdaq
- Market Cap
- EVAX 17.8M
- ATHA 16.8M
- IPO Year
- EVAX 2021
- ATHA 2020
- Fundamental
- Price
- EVAX $6.70
- ATHA $4.09
- Analyst Decision
- EVAX Strong Buy
- ATHA
- Analyst Count
- EVAX 2
- ATHA 0
- Target Price
- EVAX $13.50
- ATHA N/A
- AVG Volume (30 Days)
- EVAX 894.4K
- ATHA 32.0K
- Earning Date
- EVAX 11-07-2025
- ATHA 11-07-2025
- Dividend Yield
- EVAX N/A
- ATHA N/A
- EPS Growth
- EVAX N/A
- ATHA N/A
- EPS
- EVAX N/A
- ATHA N/A
- Revenue
- EVAX $3,176,000.00
- ATHA N/A
- Revenue This Year
- EVAX $129.34
- ATHA N/A
- Revenue Next Year
- EVAX N/A
- ATHA N/A
- P/E Ratio
- EVAX N/A
- ATHA N/A
- Revenue Growth
- EVAX 1042.45
- ATHA N/A
- 52 Week Low
- EVAX $1.20
- ATHA $2.20
- 52 Week High
- EVAX $15.50
- ATHA $8.26
- Technical
- Relative Strength Index (RSI)
- EVAX 54.71
- ATHA 62.80
- Support Level
- EVAX $5.29
- ATHA $3.78
- Resistance Level
- EVAX $6.82
- ATHA $4.23
- Average True Range (ATR)
- EVAX 1.23
- ATHA 0.23
- MACD
- EVAX -0.22
- ATHA -0.06
- Stochastic Oscillator
- EVAX 20.53
- ATHA 70.05
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.